Skip to main content

ICH Q9 Quality risk management (EMA/CHMP/ICH/24235/2006)

 ICH Q9 is a guideline titled "Quality Risk Management" (EMA/CHMP/ICH/24235/2006). This guideline was developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations on implementing a systematic approach to quality risk management (QRM) within the pharmaceutical industry. QRM is a critical process for identifying, assessing, controlling, and communicating risks to ensure product quality, safety, and efficacy. Here's an elaboration of ICH Q9:


1. Purpose of ICH Q9:

The primary purpose of ICH Q9 is to promote the integration of quality risk management principles into the pharmaceutical quality system. The guideline provides a structured approach to identify, analyze, and manage risks associated with pharmaceutical products and processes.

2. Scope:

ICH Q9 applies to all aspects of pharmaceutical manufacturing, including product development, manufacturing, quality control, and post-marketing phases. It is intended to be a comprehensive approach to managing risks across the product lifecycle.

3. Risk-Based Decision-Making:

A fundamental principle of ICH Q9 is risk-based decision-making. It encourages pharmaceutical companies to prioritize and focus their resources on managing risks that have the greatest potential impact on product quality and patient safety.

4. Risk Assessment:

The guideline provides guidance on conducting risk assessments to systematically identify and evaluate risks. The risk assessment process includes the identification of hazards, risk analysis, risk evaluation, and risk control strategies.

5. Risk Control:

ICH Q9 emphasizes the importance of implementing risk control measures to reduce or mitigate identified risks. Risk control strategies may include process improvements, changes in specifications, or enhanced monitoring.

6. Risk Communication:

Effective communication of risks within the organization and to relevant stakeholders is crucial. The guideline encourages open and transparent communication to ensure that everyone involved understands the identified risks and risk control measures.

7. Documentation:

Comprehensive documentation of risk management activities is essential. Manufacturers should maintain records of risk assessments, risk control strategies, and risk reviews.

8. Lifecycle Approach:

ICH Q9 promotes a lifecycle approach to risk management. Risks should be continuously assessed and managed throughout the product's lifecycle, from development to post-marketing phases.

9. Integration with Quality Systems:

The guideline underscores the importance of integrating QRM principles into the overall pharmaceutical quality system. This includes alignment with existing quality management processes, such as Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

10. Regulatory Considerations:

- Regulatory authorities expect pharmaceutical companies to implement QRM practices. Manufacturers should include risk assessments and risk management documentation in regulatory submissions and be prepared to discuss risk management strategies during regulatory inspections.

11. Training and Competence:

- Personnel involved in QRM activities should receive appropriate training and possess the necessary competence to carry out risk assessments and risk management effectively.

12. Continuous Improvement:

- ICH Q9 promotes a culture of continuous improvement in risk management. Companies should learn from experience, monitor the effectiveness of risk control measures, and adjust their strategies as needed.


In summary, ICH Q9 provides a structured and systematic approach to quality risk management within the pharmaceutical industry. By implementing the principles outlined in this guideline, pharmaceutical companies can better identify, assess, and control risks associated with their products and processes, ultimately leading to improved product quality and patient safety

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more